Department of Radiology, RoMed Klinikum Rosenheim, Rosenheim, Germany.
Department of Urology, RoMed Klinikum Rosenheim, Rosenheim, Germany.
Urol Int. 2022;106(1):56-62. doi: 10.1159/000515651. Epub 2021 May 7.
The objective of this study is to evaluate prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET/CT)-based primary staging in exclusively D'Amico intermediate-risk prostate cancer (PCa) patients.
We relied on the Braunschweig institutional database and retrospectively identified D'Amico intermediate-risk PCa patients who were administered to 68Ga-PSMA PET/CT-based primary staging prior to consecutive radical prostatectomy and extended lymph node dissection. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the detection of lymph node metastases were analyzed per-patient (n = 39), per-pelvic side (n = 78), and per-anatomic-region (external iliac artery and vein left/right vs. obturator fossa left/right vs. internal iliac artery left/right) (n = 203), respectively.
Sensitivity, specificity, PPV, and NPV per-patient were 20.0, 94.1, 33.3, and 88.9%, respectively. Sensitivity, specificity, PPV, and NPV per-pelvic-side were 16.7, 97.2, 33.3, and 93.3%, respectively. Sensitivity, specificity, PPV, and NPV per-anatomic-region were 16.7, 99.0, 33.3, and 97.5%, respectively.
We recorded high rates of specificity and NPV for 68Ga-PSMA PET/CT-based primary staging in D'Amico intermediate-risk PCa patients. Conversely, the sensitivity and PPV were lower than anticipated. Larger and favorably prospective trials are needed to verify our results and to unravel possible bias from such smaller studies.
本研究旨在评估仅适用于 D'Amico 中危前列腺癌(PCa)患者的前列腺特异性膜抗原正电子发射断层扫描-计算机断层扫描(PSMA PET/CT)的原发分期。
我们依赖于不伦瑞克机构数据库,回顾性地确定了在连续根治性前列腺切除术和扩大淋巴结清扫术之前接受 68Ga-PSMA PET/CT 原发分期的 D'Amico 中危 PCa 患者。分析了每位患者(n=39)、每个骨盆侧(n=78)和每个解剖区域(左/右髂外动脉和静脉与左/右闭孔窝、左/右髂内动脉)(n=203)的淋巴结转移检测的敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV)。
每位患者的敏感性、特异性、PPV 和 NPV 分别为 20.0%、94.1%、33.3%和 88.9%。每个骨盆侧的敏感性、特异性、PPV 和 NPV 分别为 16.7%、97.2%、33.3%和 93.3%。每个解剖区域的敏感性、特异性、PPV 和 NPV 分别为 16.7%、99.0%、33.3%和 97.5%。
我们记录了 D'Amico 中危 PCa 患者基于 68Ga-PSMA PET/CT 的原发分期的高特异性和 NPV 率。相反,敏感性和 PPV 低于预期。需要更大和有利的前瞻性试验来验证我们的结果,并揭示来自这些较小研究的可能偏见。